- Home
- ACTU vs THTX Comparison
ACTU vs THTX Comparison
Compare ACTU & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- THTX
- Stock Information
- Founded
- ACTU 2015
- THTX 1993
- Country
- ACTU United States
- THTX Canada
- Employees
- ACTU N/A
- THTX N/A
- Industry
- ACTU
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- ACTU
- THTX Health Care
- Exchange
- ACTU NYSE
- THTX Nasdaq
- Market Cap
- ACTU 135.0M
- THTX 119.1M
- IPO Year
- ACTU 2024
- THTX N/A
- Fundamental
- Price
- ACTU $7.47
- THTX $2.53
- Analyst Decision
- ACTU Strong Buy
- THTX Hold
- Analyst Count
- ACTU 1
- THTX 1
- Target Price
- ACTU $20.00
- THTX N/A
- AVG Volume (30 Days)
- ACTU 88.2K
- THTX 139.5K
- Earning Date
- ACTU 05-15-2025
- THTX 07-09-2025
- Dividend Yield
- ACTU N/A
- THTX N/A
- EPS Growth
- ACTU N/A
- THTX N/A
- EPS
- ACTU N/A
- THTX N/A
- Revenue
- ACTU N/A
- THTX $88,666,000.00
- Revenue This Year
- ACTU N/A
- THTX N/A
- Revenue Next Year
- ACTU N/A
- THTX $15.13
- P/E Ratio
- ACTU N/A
- THTX N/A
- Revenue Growth
- ACTU N/A
- THTX 13.52
- 52 Week Low
- ACTU $5.51
- THTX $1.12
- 52 Week High
- ACTU $11.99
- THTX $3.13
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- THTX 49.00
- Support Level
- ACTU N/A
- THTX $2.38
- Resistance Level
- ACTU N/A
- THTX $2.68
- Average True Range (ATR)
- ACTU 0.00
- THTX 0.09
- MACD
- ACTU 0.00
- THTX -0.02
- Stochastic Oscillator
- ACTU 0.00
- THTX 51.72
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.